Surface Oncology Appoints Carsten Brunn to Board of Directors

...ology(Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the companys board of ...
Read Full Article